Study exposes widespread inaccuracies in cannabidiol product labeling

Study reveals significant discrepancies in the labeled and actual cannabidiol content in various commercial products, highlighting a major quality control issue.

EMA accepts Deciphera’s MAA for cell tumour treatment for review

Vimseltinib is intended to treat tenosynovial giant cell tumour. Credit: crystal light / Shutterstock. The European Medicines Agency (EMA) has accepted for review the marketing

July 19, 2024

BrainStorm withdraws ALS drug application after negative adcomm vote

BrainStorm Cell Therapeutics is pulling its application for a controversial ALS drug a few weeks after a group of outside experts said the drug likely

October 19, 2023

Novo’s Catalent deal is great for GLP-1s. But what about drug manufacturing?

Sixteen billion dollars is a lot of money. But Monday’s announcement that the parent company of Novo Nordisk, the maker of the weight loss drug

February 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.